This proposed class action is brought against Aurora Cannabis Inc. and its subsidiaries Aurora Cannabis Enterprises Inc. and MedReleaf Corp., on behalf of a proposed class of all Canadians who purchased the Defendants’ cannabis products after February 1, 2014, and a subclass of all Class Members who developed Cannabis Hyperemesis Syndrome (CHS) after consuming one or more of the Defendants’ cannabis products.
Summary of the Proceedings
This proposed class action is brought by the Plaintiff, V.T., on behalf of all Canadians who purchased cannabis products manufactured by the Defendants Aurora Cannabis Inc., Aurora Cannabis Enterprises Inc. and/or MedReleaf Corp. after February 1, 2014, (the “Class Members”), and a subclass of all Class Members who developed Cannabis Hyperemesis Syndrome (“CHS”) after consuming one or more of the Defendants’ cannabis products (the “Subclass Members”).
The claim alleges that the Defendants negligently failed to warn consumers, patients and their treating professionals of the risk of CHS posed by ordinary use of their cannabis products.
CHS is a dangerous side effect from the ordinary use of cannabis products. CHS causes recurrent, intense and persistent nausea, abdominal pain, vomiting and loss of appetite. Severe CHS can cause dehydration, damage to the tissues of the mouth and throat, organ failure and, in extreme cases even death. It is estimated that thousands of Canadians suffer from CHS every year.
The claim alleges that the Defendants knew, or should have known, of the risk of CHS from the ordinary use of their cannabis products, but failed to provide any warning at all of either the risk of CHS, or its diagnosis and treatment. This failure is alleged to be particularly egregious given that cannabis products are often recommended by healthcare professionals to treat nausea and lack of appetite, which paradoxically are common symptoms of CHS.
The claim alleges that the Defendants’ failure to warn about the risk of CHS was negligent, and a breach of provincial consumer protection statutes. The Plaintiff seeks to recover damages for the Subclass Members who were physically and psychologically harmed when they developed CHS, as well as disgorgement of the amounts overpaid by Class and Subclass Members for the cannabis products purchased from the Defendants.
Status of the Proceedings
The claim was commenced by Statement of Claim on November 15, 2022.
Did you develop CHS following the use of the Defendants’ cannabis products, or did you purchase and use the Defendants’ cannabis products after February 1, 2014?
If so, we would like to hear from you. Please contact Adam Babiak at 647.313.1894 or email reception@waddellphillips.ca re: “Cannabis Hyperemesis Syndrome Class Action”, or fill in the form at the “Contact Us” link below.
Summary of the Proceedings
This proposed class action is brought by the Plaintiff, V.T., on behalf of all Canadians who purchased cannabis products manufactured by the Defendants Aurora Cannabis Inc., Aurora Cannabis Enterprises Inc. and/or MedReleaf Corp. after February 1, 2014, (the “Class Members”), and a subclass of all Class Members who developed Cannabis Hyperemesis Syndrome (“CHS”) after consuming one or more of the Defendants’ cannabis products (the “Subclass Members”).
The claim alleges that the Defendants negligently failed to warn consumers, patients and their treating professionals of the risk of CHS posed by ordinary use of their cannabis products.
CHS is a dangerous side effect from the ordinary use of cannabis products. CHS causes recurrent, intense and persistent nausea, abdominal pain, vomiting and loss of appetite. Severe CHS can cause dehydration, damage to the tissues of the mouth and throat, organ failure and, in extreme cases even death. It is estimated that thousands of Canadians suffer from CHS every year.
The claim alleges that the Defendants knew, or should have known, of the risk of CHS from the ordinary use of their cannabis products, but failed to provide any warning at all of either the risk of CHS, or its diagnosis and treatment. This failure is alleged to be particularly egregious given that cannabis products are often recommended by healthcare professionals to treat nausea and lack of appetite, which paradoxically are common symptoms of CHS.
The claim alleges that the Defendants’ failure to warn about the risk of CHS was negligent, and a breach of provincial consumer protection statutes. The Plaintiff seeks to recover damages for the Subclass Members who were physically and psychologically harmed when they developed CHS, as well as disgorgement of the amounts overpaid by Class and Subclass Members for the cannabis products purchased from the Defendants.
Status of the Proceedings
The claim was commenced by Statement of Claim on November 15, 2022.
Did you develop CHS following the use of the Defendants’ cannabis products, or did you purchase and use the Defendants’ cannabis products after February 1, 2014?
If so, we would like to hear from you. Please contact Adam Babiak at 647.313.1894 or email reception@waddellphillips.ca re: “Cannabis Hyperemesis Syndrome Class Action”, or fill in the form at the “Contact Us” link below.
Updates about this proposed class action will be posted as they become available.
We review every inquiry we receive and will respond promptly to case specific inquiries.
Contact us below and we’ll respond shortly.